Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the genomic landscape of Waldenström’s macroglobulinemia and how it impacts treatment strategies. A variety of targets are discussed. Specifically highlighted is the MYD88 mutation, which Dr Castillo considers one of the biggest advancements in Waldenström’s in 75 years. Finally, novel agents for WM are discussed. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics